SCHEMBL2265043

SCHEMBL2265043

O=C1c2ccc(S(=O)(=O)Cl)cc2C(=O)c2ccc(S(=O)(=O)Cl)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
TDP2 O95551 1/20 0.47
NSD2 O96028 1/20 0.47
HK1 P19367 1/20 0.47
PAX8 Q06710 1/20 0.47
PARG Q86W56 6/20 0.46
ESR1 P03372 1/20 0.44
MAOA P21397 1/20 0.44
UGT1A1 P22309 1/20 0.44
MAOB P27338 1/20 0.44
ESR2 Q92731 1/20 0.44
ALDH1A1 P00352 4/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31121547 1.00 PKM (0.47) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL55616 1.00 PKM (0.47) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL2264974 0.95 PKM (0.48) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL30007977 0.94 KMT2A (0.56) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL919135 0.94 KMT2A (0.56) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL21104695 0.92 SMN1; SMN2 (0.54) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL10070529 0.90 PARG (0.44) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL25171455 0.89 TDP2 (0.56) PKMSMN1; SMN2KMT2AMAPK1MEN1
Dioxane SCHEMBL28440846 0.84 PARG (0.49) PKMSMN1; SMN2KMT2AMAPK1MEN1
SCHEMBL11856834 0.81 SMN1; SMN2 (0.46) PKMSMN1; SMN2KMT2AMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543209-A1 PROCESS FOR MANUFACTURING AN AQUEOUS HYDROGEN PEROXIDE SOLUTION SOLVAY SA (BE) 2019-09-25 EP disclosed
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed
US-20100222454-A1 DEGRADATION ACCELERATOR FOR POLYMERS AND POLYMER ARTICLE COMPRISING IT CIBA CORPORATION (US) 2010-09-02 US disclosed
US-20100222454-A1 DEGRADATION ACCELERATOR FOR POLYMERS AND POLYMER ARTICLE COMPRISING IT CIBA CORPORATION (US) 2010-09-02 US disclosed
WO-2009016083-A1 DEGRADATION ACCELERATOR FOR POLYMERS AND POLYMER ARTICLE COMPRISING IT BASF SE (CH) 2009-02-05 WO disclosed
EP-1377536-A4 SELF-REDUCING ANTHRAQUINONE COMPOUNDS COMMW SCIENT AND RES ORGANISAT (AU) 2007-02-28 EP disclosed
EP-1351948-A4 NEW OXYGEN SCAVENGING COMPOSITIONS COMMW SCIENT IND RES ORG (AU) 2005-06-29 EP disclosed
EP-0833626-A1 MONO- AND DISULFO-SUBSTITUTED ANTHRAQUINONES AND THEIR USE FOR THE TREATMENT OF BONE MATRIX DISORDERS Boonville Limited (VG) 1998-04-08 EP disclosed
WO-1997000675-A1 MONO- AND DISULFO-SUBSTITUTED ANTHRAQUINONES AND THEIR USE FOR THE TREATMENT OF BONE MATRIX DISORDERS BOONVILLE LIMITED (VG) 1997-01-09 WO disclosed
EP-0673348-A1 PRODUCTION OF HYDROGEN PEROXIDE GUILLET, James Edwin (CA) 1995-09-27 EP disclosed
WO-1995010480-A1 PRODUCTION OF HYDROGEN PEROXIDE GUILLET JAMES E (CA) 1995-04-20 WO disclosed
EP-0024746-B1 PROCESS FOR THE ABSORPTION AND REMOVAL OF HYDROGEN SULPHIDE AS ELEMENTAL SULPHUR FROM GASES OR GAS MIXTURES, AND AN ALKALINE SOLUTION CONTAINING A DERIVATIVE OF ANTHRAQUINONE SULFONIC ACID AMIDE CIBA-GEIGY AG (CH) 1983-03-02 EP disclosed
EP-0008641-B1 ANTHRAQUINONESULPHONAMIDES AND PROCESS FOR THEIR MANUFACTURE CIBA-GEIGY AG (CH) 1982-01-13 EP disclosed
US-4276224-A Anthraquinone sulphonamide compounds and preparation CIBA-GEIGY CORPORATION (US) 1981-06-30 US disclosed
EP-0024746-A1 Process for the absorption and removal of hydrogen sulphide as elemental sulphur from gases or gas mixtures, and an alkaline solution containing a derivative of anthraquinone sulfonic acid amide CIBA-GEIGY AG (CH) 1981-03-11 EP disclosed
EP-0008641-A1 Anthraquinonesulphonamides and process for their manufacture CIBA-GEIGY AG (CH) 1980-03-19 EP disclosed
US-3983248-A VIRICIDES RICHARDSON-MERRELL INC. (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 PKM 2733/4885SMN1; SMN2 1010/4885KMT2A 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.